International research led by the Translational Synthetic Biology Laboratory of the Department of Medicine and Life Sciences (MELIS) at Pompeu Fabra University has succeeded in efficiently engineering Cutibacterium acnes -a type of skin bacterium- to produce and secrete a […]
AOBiome Therapeutics Inc. (“AOB”), a leading clinical-stage microbiome company focusing on inflammatory conditions, announced today that is has entered into an exclusive license and development agreement with Maruho Co., Ltd., to develop and commercialize AOB’s […]
The European Investment Bank (EIB) has signed a €20 million venture debt financing agreement with The Akkermansia Company, a Belgian company specialising in microbiome health, backed by the European Commission’s InvestEU initiative. Started as a spin-off […]
COPENHAGEN, Denmark–(BUSINESS WIRE)–Freya Biosciences, a trans-Atlantic biotech company specializing in women’s health, announced today a $38 million Series A financing – one of the largest raises to advance women’s reproductive immunotherapies. Led by Sofinnova Partners […]
Introduction Until now, enumeration of bacteria by plate counts has been the de facto gold standard to evaluate the potency of live biotherapeutic and probiotic products. Nonetheless the method has clear limitations such as low […]
Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research & development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. The deal provides Ferring with exclusive rights to […]
L’Oréal announced that it has completed the acquisition of Lactobio, a leading probiotic and microbiome research company based in Copenhagen. The strategic acquisition builds on 20 years of advanced research by L’Oréal into the microbiome scientific […]
Paris, FRANCE – December 5 2023 – Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B […]
Recently, the United States Food and Drug Administration (US FDA) has taken several steps to tackle the selling of non-pharmaceutical grade probiotic products to healthcare providers for the treatment and prevention of disease in preterm […]
Cambridge, MA & NESS ZIONA, Israel – November 29, 2023 – BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, […]
Vedanta Biosciences, a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta’s foundational […]